

# Barbara C Tilley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4287995/publications.pdf>

Version: 2024-02-01

18  
papers

743  
citations

687363

13  
h-index

839539

18  
g-index

18  
all docs

18  
docs citations

18  
times ranked

1113  
citing authors

#	ARTICLE	IF	CITATIONS
1	Using increased trust in medical researchers to increase minority recruitment: The RECRUIT cluster randomized clinical trial. <i>Contemporary Clinical Trials</i> , 2021, 109, 106519.	1.8	8
2	Intent-to-treat analysis of cluster randomized trials when clusters report unidentifiable outcome proportions. <i>Clinical Trials</i> , 2020, 17, 627-636.	1.6	4
3	Cost-effectiveness evaluation of the PROPPR trial transfusion protocols. <i>Transfusion</i> , 2020, 60, 922-931.	1.6	1
4	Cross-cultural Differences of the Non-motor Symptoms Studied by the Traditional Chinese Version of the International Parkinson and Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 68-77.	1.5	29
5	Caffeine, creatine, GRIN2A and Parkinson's disease progression. <i>Journal of the Neurological Sciences</i> , 2017, 375, 355-359.	0.6	23
6	Design of a cluster-randomized minority recruitment trial: RECRUIT. <i>Clinical Trials</i> , 2017, 14, 286-298.	1.6	23
7	Validation of the Hebrew version of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 7-12.	2.2	9
8	Communicating with participants during the conduct of multi-center clinical trials. <i>Clinical Trials</i> , 2016, 13, 592-596.	1.6	7
9	Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial. <i>Transfusion</i> , 2015, 55, 1331-1339.	1.6	73
10	Handling missing values in the MDS-UPDRS. <i>Movement Disorders</i> , 2015, 30, 1632-1638.	3.9	33
11	Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 584.	7.4	192
12	Caffeine and Progression of Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2015, 38, 163-169.	0.7	25
13	Official Japanese Version of the International Parkinson and Movement Disorder Society's Unified Parkinson's Disease Rating Scale: Validation Against the Original English Version. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 200-212.	1.5	47
14	<sc>IPMDS</sc>'s sponsored Scale Translation Program: Process, Format, and Clinimetric Testing Plan for the <sc>MDS</sc>'s <sc>UPDRS</sc> and UDysRS. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 97-101.	1.5	30
15	Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: Design, rationale and implementation. <i>Injury</i> , 2014, 45, 1287-1295.	1.7	118
16	A randomized recruitment intervention trial in Parkinson's disease to increase participant diversity: early stopping for lack of efficacy. <i>Clinical Trials</i> , 2012, 9, 188-197.	1.6	26
17	Caffeine and Progression of Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2008, 31, 189-196.	0.7	35
18	The Next Step Trial: Impact of a Worksite Colorectal Cancer Screening Promotion Program. <i>Preventive Medicine</i> , 1999, 28, 276-283.	3.4	60